This Website uses cookies which are essential for providing our services and core website functionality. In addition, if you click on "I AGREE", we will further use analytical and advertising cookies to analyse your use of our Website so that we can improve its functionality and display content tailored according to your interests and preferences, including on third party websites. We use Google Analytics and its tracking and remarketing features connected with Google Ads. This means that cookies on your device will be placed and accessed by Google LLC in the USA enabling us and third parties participating in the Google advertising network to conduct conversion tracking and remarketing activities across different websites and devices. By accepting analytical and advertising cookies you consent to the respective processing and sharing of your personal data with Google LLC. You can withdraw your consent and change your cookie preferences at any time by using our Cookie preferences tool . To refuse consent and continue without analytical and advertising cookies, please click on "I DO NOT AGREE". For more information see our Privacy policy .

logo

Passion for Innovation. Compassion for Patients.™

Daiichi Sankyo Europe GmbH

Our Cardiovascular Commitment

“We strive to help patients with cardiovascular diseases by developing innovative treatments. Since 2002 our cardiovascular treatments have improved outcomes of over 40 million* patients across Europe.”

We are the pioneer behind leading pharmaceuticals such as

  • Adrenalin (an adrenal cortex hormone agent that became the first blockbuster medicine of the 20th century) 
  • Pravastatin (a globally groundbreaking anti-hyperlipidemic agent)

Our current cardiovascular portfolio includes products for

  • Atrial fibrillation
  • Hypertension
  • Thrombotic disorders

 

*40 million patients treated with olmesartan and its combinations, prasugrel, edoxaban, pravastatin in selected countries

More Stories

Atrial Fibrillation: Check your pulse

Trudie Lobban MBE on the importance of taking your pulse

Featured Stories

Edoxaban

Edoxaban is a once-daily, non-vitamin K antagonist (non-VKA) oral anticoagulant (NOAC) that specifically, reversibly and directly inhibits factor Xa, an important factor in the coagulation system that leads to blood clotting. read more ...

Prasugrel

Our oral antiplatelet agent prasugrel2 helps to keep blood platelets from clotting together and developing a blockage in arteries in patients who had an acute coronary syndrome (ACS) and underwent a percutaneous coronary intervention (PCI). read more ...

Olmesartan

High blood pressure is one of the most common causes of cardiovascular diseases in the world. Olmesartan is an angiotensin receptor blocker (ARB) with excellent blood pressure lowering efficacy. read more ...